Veracyte, Inc. (VCYT)

Over the past six months, Veracyte's stock has experienced several notable events and fluctuations. The share price was $30.01 as of March 27, 2026, a slight decline from $30.12 on March 28, 2025. The stock's 52-week range has been between $22.61 and $50.71. Key events include the acquisition of C2i Genomics, financial results showing increased revenue and testing volume, participation in investor conferences, insider selling, JPMorgan Chase & Co. increasing its stake, and the divestiture of its French contract manufacturing business.

Veracyte's operations are influenced by seasonal trends in different regions and the seasonality of customer budgets. The mix of domestic versus international sales can also impact demand. The company anticipates lower adjusted EBITDA margins in the first quarter due to typical seasonality of expenses, including increased compensation, benefits, and payroll tax. Forecasting customer demand can be challenging for Veracyte.

Veracyte, Inc. is a global genomic diagnostics company focused on transforming cancer care through molecular diagnostics. The company operates within the Healthcare sector, specifically in the Diagnostics & Research, Medical Specialties, and Healthcare Facilities industries. Veracyte's diagnostic platform leverages broad genomic and clinical data, bioinformatics, and AI capabilities to deliver high-performing cancer tests. Major products and services include Afirma Genomic Sequencing Classifier and Xpression Atlas for thyroid cancer diagnosis, Percepta Bronchial Genomic Classifier and Percepta Nasal Swab Test for lung cancer diagnosis, Envisia Genomic Classifier for idiopathic pulmonary fibrosis diagnosis, Prosigna Breast Cancer Prognostic Gene Signature Assay for breast cancer treatment decisions, Decipher Prostate Genomic Classifiers for prostate cancer risk assessment, Decipher Bladder Genomic Classifier for bladder cancer diagnosis, nCounter analysis system services, and pipeline products like TrueMRD, LymphMark, and Percepta Genomic Atlas.

Veracyte is headquartered in South San Francisco, California, and has additional offices in San Diego, California, Austin, Texas, and Haifa, Israel. Its key geographic markets include North America, Europe, and the Middle East. Veracyte is actively pursuing global expansion, particularly outside the United States, by distributing its Prosigna test as an in vitro diagnostic test to local laboratories and hospitals.

Veracyte has established a strong brand reputation within the genomic diagnostics industry, primarily driven by its innovative and high-performing diagnostic tests. The company's products are included in major clinical guidelines, which supports broad adoption and reinforces its credibility. Veracyte is recognized for combining genomic data and artificial intelligence to create precise diagnostic tests that empower clinicians with valuable insights to guide patient care in cancer diagnosis and treatment. The company's research-use-only Afirma Genomic Resource for Intelligent Discovery (GRID) offering is gaining traction in academic settings. General risks such as difficulty meeting market demand or quality standards could potentially harm its reputation.

Veracyte, Inc. has a significant institutional ownership concentration, remaining above 90% in early 2026. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Artisan Partners Limited Partnership, Fmr Llc, State Street Corp, ARK Investment Management LLC, Dimensional Fund Advisors Lp, Wellington Management Group Llp, Geode Capital Management, Llc, ArrowMark Colorado Holdings LLC, and JPMorgan Chase & Co. Key individual insider holders include Marc Stapley, Bonnie H Anderson, Rebecca Chambers, Phillip G. Febbo, John Leite, and Karin Eastham.